Item 5.07 Submission of Matters to a Vote of Security Holders.




On June 8, 2021, NGM Biopharmaceuticals, Inc. (the "Company") held its 2021
annual meeting of stockholders (the "Annual Meeting"). The following is a brief
description of each matter voted on at the Annual Meeting, as well as the number
of votes cast for and against each matter, and if applicable, the number of
abstentions and broker non-votes with respect to each matter. A more complete
description of each matter can be found in the Company's definitive proxy
statement filed with the U.S. Securities and Exchange Commission on April 28,
2021.



1. Election of Directors




Director Name                         Votes For          Votes Against         Votes Withheld         Broker Non-Votes
Jin-Long Chen, Ph.D.                   55,573,873                     0              7,840,620                5,806,958
Roger M. Perlmutter, M.D., Ph.D.       63,369,234                     0                 45,259                5,806,958


The Class II director nominees were elected to hold office until the Company's
2024 annual meeting of stockholders and until their successors are duly elected
and qualified.



2. Ratification of Selection of Independent Registered Public Accounting Firm




Firm                 Votes For        Votes Against       Abstentions      Broker Non-Votes
Ernst & Young LLP     69,181,486              25,320            14,645                     0

The Company's stockholders ratified the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2021.

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses